NEWS

Media

30

September | 2021

Cannabics Announces New Corporate Logo, New Website and New Company Presentation

TEL AVIV, Israel and BETHESDA, Maryland, Sep. 30, 2021 a global leader in the development of cancer related cannabinoid-based medicine and a pioneer

22

September | 2021

Gabriel Yariv, Executive Director of Cannabics Pharmaceuticals and Dr. David Sans will participate at the ICDP Summit in Boston

TEL AVIV, Israel and BETHESDA, Maryland, Sep 22, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer rela

21

September | 2021

Cannabics Pharmaceuticals hires Healthcare Investment Banker Dr. David Sans in New York to expand CNBX in Mental Health Diseases

TEL AVIV, Israel and BETHESDA, Maryland, Sep 21, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer rela

13

September | 2021

Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine

TEL AVIV, Israel and BETHESDA, Maryland, Sep 13, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX),a global leader in the development of cancer relat

23

August | 2021

Hemato-Oncology Expert, Dr. Sigal Tavor (MD) Joins Cannabics Pharmaceuticals’ Board of Advisors

TEL AVIV, Israel and BETHESDA, Maryland, Aug 23, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX),a global leader in the development of cancer relat

04

August | 2021

World-Renowned Melanoma Expert Joins Cannabics Pharmaceuticals’ Board of Advisors

TEL AVIV, Israel and BETHESDA, Maryland, Aug 04, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer rela

20

July | 2021

Cannabics Pharmaceuticals Appoints a Second Independent Board Member

TEL AVIV, Israel and BETHESDA, Maryland, Jul 20, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer rela

07

July | 2021

Cannabics Pharmaceuticals Announces Appointment of New Independent Board Member

TEL AVIV, Israel and BETHESDA, Maryland, Jun 28, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer rela

28

June | 2021

Cannabics Pharmaceuticals’ Drug Candidate Exhibits 30% Tumor Volume Reduction in Mice

TEL AVIV, Israel and BETHESDA, Maryland, Jun 28, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer rela

17

June | 2021

Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseases

TEL AVIV, Israel and BETHESDA, Maryland, Jun 17, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer rela

03

June | 2021

Cannabics Pharmaceuticals Launches a Breast Cancer Treatment Research Program

TEL AVIV, Israel and BETHESDA, Maryland, Jun 03, 2021 The announcement comes following the launching of a Melanoma research program in April 2021, an

25

May | 2021

The European Patent Office Grants Cannabics Pharmaceuticals Patent for Company’s Personalized Medicine Drug Discovery Technology

TEL AVIV, Israel and BETHESDA, Maryland, May 25, 2021 Cannabics Pharmaceuticals Inc. (CNBX), a global leader in the development of cancer related can

11

May | 2021

Cannabics Pharmaceuticals Receives Patent “Notice of Allowance” From The Mexican Patent and Trademark Office (IMPI)

TEL AVIV, Israel and BETHESDA, Maryland, May 11, 2021 Cannabics Pharmaceuticals Inc. (CNBX), a global leader in the development of cancer related can

06

May | 2021

Cannabics Pharmaceuticals Receives Patent “Notice of Allowance” From The Mexican Patent and Trademark Office (IMPI)

TEL AVIV, Israel and BETHESDA, Maryland, May 6, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer relat

29

April | 2021

Cannabics Pharmaceuticals Launches a New Research Program to develop a Melanoma Treatment Drug Candidate for FDA Approval Track

  TEL AVIV, Israel and BETHESDA, Maryland, April 26, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of

20

April | 2021

Cannabics Pharmaceuticals’ Drug Candidate RCC-33 Prolongs Survival Rate in Mice Inoculated with Human Colorectal Cancer Cells

  TEL AVIV, Israel and BETHESDA, Md., March 17, 2021 /PRNewswire/ Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the develo

31

March | 2021

Cannabics Pharmaceuticals to Initiate in-vivo Dose Response Study on Proprietary Colorectal Cancer Drug Candidate RCC-33

  TEL AVIV, Israel and BETHESDA, Md., March 31, 2021 /PRNewswire/ Cannabics Pharmaceuticals Inc. (OTCQB: CNBX),  a global leader in the devel

17

March | 2021

Cannabics Pharmaceuticals’ Drug Candidate RCC-33 Prolongs Survival Rate in Mice Inoculated with Human Colorectal Cancer Cells

  TEL AVIV, Israel and BETHESDA, Md., March 17, 2021 /PRNewswire/ Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the develo

17

February | 2021

Cannabics Pharmaceuticals’ in-vivo Tumor Inhibitory Effect Study Concludes with a Statistical Significance of p ≤ 0.016

  TEL AVIV, Israel and BETHESDA, Maryland, Feb. 17, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of

16

February | 2021

Cannabics Pharmaceuticals’ in-vivo Study concludes with a 33% Lower Tumor Volume in Mice Treated with Company’s Proprietary Drug Candidate for Colorectal Cancer

  TEL AVIV, Israel and BETHESDA, Maryland, Feb. 16, 2021 /PRNewswire/ Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the de

03

February | 2021

Cannabics Pharmaceutical’s Interim in-vivo Study Results Show a 27% Lower Tumor Volume in Mice Treated with Company’s Proprietary Drug Candidate for Colorectal Cancer

  TEL AVIV, Israel and BETHESDA, Maryland, Feb. 3, 2021 /PRNewswire/ Cannabics Pharmaceuticals Inc. (OTCQB:CNBX ), a global leader in the develop

21

December | 2020

Cannabics Pharmaceuticals Initiates In-Vivo Animal Studies for FDA Pre-IND Meeting Package

TEL AVIV, Israel and BETHESDA, Maryland, Dec. 21, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. Dec 21, 2020, 09:27 ET (OTCQB: CNBX), a globa

16

November | 2020

Cannabics Pharmaceuticals Founds Digestix Bioscience Inc., a Subsidiary for Treatment of Precancerous and Early Stage Neoplastic Local Tumors

Cannabics Pharmaceuticals Founds Digestix Bioscience Inc., a Subsidiary for Treatment of Precancerous and Early Stage Neoplastic Local Tumors Nov 16,

09

November | 2020

Cannabics Concludes a Pre-Clinical Study on Human Biopsies in Preparation for FDA pre-IND Meeting Request on Colorectal Cancer Drug Candidate RCC-33

TEL AVIV, Israel and BETHESDA, Md., Nov. 9, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related can

27

October | 2020

Cannabics Pharmaceuticals receives “Intention to Grant a European Patent” notice for its System and Method for High Throughput Screening of Cancer Cells patent application

TEL AVIV, Israel and BETHESDA, Maryland, Oct. 27, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer relat

21

October | 2020

Cannabics Pharmaceuticals Prepares to Submit the FDA with a pre-IND Meeting Request for its Proprietary Colon Cancer Drug Candidate, CANNABICS™ RCC-33

TEL AVIV, Israel and BETHESDA, Md., Oct. 21, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related ca

20

August | 2020

Cannabics Pharmaceuticals to Establish a Division for its Antitumor Drug Candidate RCC-33

TEL AVIV, Israel and BETHESDA, Maryland, Aug. 20, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focu

05

August | 2020

Cannabics Pharmaceuticals Appoints Dr. Dana Ben-Ami Shor (MD), Gastroenterologist, to its Scientific Board of Advisors

TEL AVIV, Israel and BETHESDA, Md., Aug. 5, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on

14

July | 2020

Cannabics Pharmaceuticals Initiates Penetration for Its Cannabinoid Diagnostic Platform Into European Markets

TEL AVIV, Israel and BETHESDA, Maryland, July 14, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focu

16

June | 2020

Cannabics Pharmaceuticals Appoints Dr. Erez Scapa, MD to its Scientific Board of Advisors

TEL AVIV, Israel and BETHESDA, Maryland, June 16, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focu

10

June | 2020

Cannabics Pharmaceuticals and Cannomed Collaborate to Develop Cannabis Strains Targeting Cancers

TEL AVIV, Israel and BETHESDA, Maryland, June 10, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focu

26

May | 2020

Cannabics Pharmaceuticals to Capitalize on Israel’s Final Approval for the Export of Medical Cannabis

TEL AVIV, Israel and BETHESDA, Maryland, May 26, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focus

06

May | 2020

Cannabics Pharmaceuticals Files Provisional Patent on Composition and Method for Treating Colon Cancer With Cannabinoids

TEL AVIV, Israel and BETHESDA, Maryland, May 6, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focu

27

April | 2020

Cannabics Pharmaceuticals Appoints Prof. Zamir Halpern to Its Scientific Board of Advisors

TEL AVIV, Israel and BETHESDA, Maryland, April 27, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine foc

13

April | 2020

Cannabics Pharmaceuticals Develops Novel Cannabis Formulation for the Treatment of Colon Cancer

TEL AVIV, Israel and BETHESDA, Maryland, April 13, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine foc

25

March | 2020

Cannabics Pharmaceuticals Study Shows Complex Combinatorial Anti-tumor Activity of Cannabinoids

TEL AVIV, Israel and BETHESDA, Maryland, March 25, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine foc

18

March | 2020

Cannabics Pharmaceuticals Offers Its High Throughput Screening (HTS) Platform to the Israeli Health Authorities for SARS-CoV-2 Research

TEL AVIV, Israel and BETHESDA, Maryland, March 18, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine foc

11

March | 2020

Cannabics Pharmaceuticals Shows Specific Cultivars Identified to Have Positive Anti-Tumor Effects on Gastric Adenocarcinoma

TEL AVIV, Israel and BETHESDA, Maryland, March 11, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabino

02

March | 2020

Cannabics Pharmaceuticals Reveals Different Extraction Methods Result in Differential Necrotic Effects of Cannabis on Gastrointestinal Cancer Cells

TEL AVIV, Israel and BETHESDA, Maryland, March 2, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabin

25

February | 2020

Cannabics Pharmaceuticals Partners With NewCanna to Commence Research Based on Colombian Indigenous Cannabis Landraces

TEL AVIV, Israel and BETHESDA, Maryland, Feb. 25, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabin